The pharmacological blockade of TRPA1 could provide an effective strategy to reduce the Ca2+-dependent recruitment of antioxidant defense and pro-survival signaling pathways in lung and breast cancers, as recently shown in [146]. This evidence concerns the gene TRPA1 and breast carcinoma.